Natrol bulks up
This article was originally published in The Tan Sheet
Supplement firm's sales increase 9.6% to $20.7 mil. in the second quarter (ended June 30), with earnings of $769,000 compared to a net loss of $246,000 in the prior-year period. Natrol has focused on its core Natrol brand following the divestment of multi-level and direct marketing businesses Annasa and Tamasa in January. Weight-loss product sales as well as the consolidation of its Prolab sports nutrition business into the firm's Chatsworth, Calif. corporate headquarters also contributed to profitability, President Elliot Balbert maintained...
You may also be interested in...
Some Authorized COVID-19 Molecular Diagnostic Tests Can Skip Forward To Market For Pooled Serial Screening
The US FDA says as long as the EUA-authorized tests provide a notification with validation data and procedural information, they can be used for pooled serial screening before additional review.
Most clinical trial sponsors view data disclosure as a mandate, maintaining regulatory compliance as a legal requirement. Study sponsors that realize the potential to repurpose this data, using a patient-first approach, turn transparency into a strategic advantage for engagement and recruitment efforts.
The Bio-Console 560 extracorporeal blood pumping console is being recalled over reports it could lose power during bypass surgery, which could lead to organ or neural dysfunction, blood clots, or even death.